Clinical Trial

Deep TMS for Comorbid Depression and Cognitive Impairment in Older Adults

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated October 27, 2025 (before its estimated August 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
In this study, the investigators will be examining the effects of the deep repetitive transcranial magnetic stimulation (rTMS) using the H1 coil in patients over the age of 60 diagnosed with mild to early-moderate Alzheimer's disease (AD) or mild cognitive impairment (MCI) and comorbid Major Depressive Disorder (MDD) who have been unable to tolerate or failed to respond to antidepressant medications. The coil was designed to stimulate deeper regions of the left dorsolateral prefrontal cortex (DLPFC). Based on prior research, the investigators propose that active stimulation with the H1 coil for 4 weeks may result in significant remission rates and will be tolerable and safe.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2018-09-07; most recent amendment 2025-10-23.
Status change: Not Yet Recruiting → Recruiting 2019-07-05
Trial Details
NCT Number NCT03665831
Lead Sponsor Rotman Research Institute at Baycrest
Collaborators: Brainsway, Centre for Addiction and Mental Health
Conditions Major Depressive Disorder, Alzheimer Disease, Mild Cognitive Impairment
Enrollment 28 participants
Start Date 2018-10-23
Primary Completion 2026-08-15 (estimated)
Study Completion 2026-09-15 (estimated)
Updated on ClinicalTrials.gov 2025-10-27